Disease-A-Month
Volume 52, Issue 1 , Pages 5-50 , January 2006

Elevated Lipoprotein(a)—A Genetic Risk Factor for Premature Vascular Disease in People With and Without Standard Risk Factors: A Review

References 

  1. Berg K . A new serum type system in man (the LP system) . Acta Pathol Microbiol Scand . 1963;59:369–382
  2. Luc G , Bard JM , Arveiler D , et al.   Lipoprotein(a) as a predictor of coronary heart disease (the PRIME Study) . Atherosclerosis . 2002;163(2):377–384
  3. Rifai N , Ma J , Sacks FM , et al.   Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men (The Physicians’ Health Study) . Clin Chem . 2004;50:1364–1371
  4. Nguyen TT , Ellefson RD , Hodge DO , et al.   Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women . Circulation . 1997;96(5):1390–1397
  5. Bostom AG , Cupples LA , Jenner JL , et al.   Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study . JAMA . 1996;276(7):544–548
  6. Dahlen GH , Srinivasan SR , Stenlund H , et al.   The importance of serum lipoprotein(a) as an independent risk factor for premature coronary artery disease in middle-aged black and white women from the United States . J Intern Med . 1998;244(5):417–424
  7. Assmann G , Schulte H , von Eckardstein A . Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men . Am J Cardiol . 1996;77(14):1179–1184
  8. Gambhir JK , Kaur H , Gambhir DS , et al.   Lipoprotein(a) as an independent risk factor for coronary artery disease in patients below 40 years of age . Indian Heart J . 2000;52(4):411–415
  9. Mohan V , Deepa R , Haranath SP , et al.   Lipoprotein(a) is an independent risk factor for coronary artery disease in NIDDM patients in South India . Diabetes Care . 1998;21(11):1819–1823
  10. Hopkins PN , Wu LL , Hunt SC , et al.   Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease . Arterioscler Thromb Vasc Biol . 1997;17(11):2783–2792
  11. von Eckardstein A , Schulte H , Cullen P , et al.   Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk . J Am Coll Cardiol . 2001;37(2):434–439
  12. Enas EA . Lipoprotein(a)is an important genetic risk for coronary artery disease in Asian Indians . Am J Cardiol . 2001;88(2):201–202
  13. Enas EA , Mehta J . Malignant coronary artery disease in young Asian Indians (Thoughts on pathogenesis, prevention, and treatment) . Clin Cardiol . 1995;18:131–135
  14. Anand S , Enas EA , Pogue J , et al.   Elevated lipoprotein(a) levels in South Asians in North America . Metabolism . 1998;47(2):182–184
  15. Enas EA , Dhawan J , Petkar S . Coronary artery disease in Asian Indians (lessons learned so far and the role of Lp(a)) . Indian Heart J . 1997;49:25–34
  16. Hoogeveen RC , Gambhir JK , Gambhir DS , et al.   Evaluation of Lp[a] and other independent risk factors for CHD in Asian Indians and their USA counterparts . J Lipid Res . 2001;42(4):631–638
  17. Lawn RM . Lipoprotein(a) in heart disease . Sci Am . 1992;266(6):54–60
  18. Koschinsky ML , Marcovina SM . Structure-function relationships in apolipoprotein(a) (insights into lipoprotein(a) assembly and pathogenicity) . Curr Opin Lipidol . 2004;15(2):167–174
  19. Boffa MB , Marcovina SM , Koschinsky ML . Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis (mechanistic insights from animal models) . Clin Biochem . 2004;37(5):333–343
  20. Koschinsky ML . Lipoprotein(a) and the link between atherosclerosis and thrombosis . Can J Cardiol . 2004;20(suppl B):37B–43B
  21. Hajjar KA , Nachman R . The role of lipoprotein(a) in atherogenesis and thrombosis . Annu Rev Med . 1996;47:423–442
  22. Naruszewicz M , Selinger E , Davignon J . Oxidative modification of lipoprotein(a) and the effect of beta-carotene . Metabolism . 1992;41(11):1215–1224
  23. Nielsen LB . Atherogenicity of lipoprotein(a) and oxidized low density lipoprotein (insight from in vivo studies of arterial wall influx, degradation and efflux) . Atherosclerosis . 1999;143(2):229–243
  24. Poon M , Zhang X , Dunsky KG , et al.   Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells . Circulation . 1997;96(8):2514–2519
  25. Grainger DJ , Kirschenlohr HL , Metcalfe JC , et al.   Proliferation of human smooth muscle cells promoted by lipoprotein(a) . Science . 1993;260(5114):1655–1658
  26. Syrovets T , Thillet J , Chapman MJ , et al.   Lipoprotein(a) is a potent chemoattractant for human peripheral monocytes . Blood . 1997;90(5):2027–2036
  27. Takami S , Yamashita S , Kihara S , et al.   Lipoprotein(a) enhances the expression of intracellular adhesion molecule-1 in cultured human umbilical vein endothelial cells . Circulation . 1998;97:721–728
  28. Sorensen KE , Celermajer DS , Georgakopoulos D , et al.   Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level . J Clin Invest . 1994;93(1):50–55
  29. Zha SP , Xu DY . Oxidized lipoprotein(a) increases the expression of platelet-derived growth factor-B in human umbilical vein endothelial cells . Clin Chim Acta . 2000;296(1-2):121–133
  30. Grainger DJ , Kemp PR , Liu AC , et al.   Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice . Nature . 1994;370(6489):460–462
  31. Lutgens E , Gijbels M , Smook M , et al.   Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression . Arterioscler Thromb Vasc Biol . 2002;22(6):975–982
  32. Deb A , Caplice N . Lipoprotein(a) (new insight into mechanisms of atherogenesis and thrombosis) . Clin Cardiol . 2004;27:258–264
  33. Morrisett JD . The role of lipoprotein[a] in atherosclerosis . Curr Atheroscler Rep . 2000;2(3):243–250
  34. Sangrar W , Bajzar L , Nesheim ME , et al.   Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation . Biochemistry . 1995;34(15):5151–5157
  35. Palabrica TM , Liu AC , Aronovitz MJ , et al.   Antifibrinolytic activity of apolipoprotein(a) in vivo (human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis) . Nat Med . 1995;1(3):256–259
  36. Loscalzo J , Weinfeld M , Fless GM , et al.   Lipoprotein(a), fibrin binding, and plasminogen activation . Arteriosclerosis . 1990;10(2):240–245
  37. Etingin OR , Hajjar DP , Hajjar KA , et al.   Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis . J Biol Chem . 1991;266(4):2459–2465
  38. Marcovina SM , Koschinsky ML . Evaluation of lipoprotein(a) as a prothrombotic factor (progress from bench to bedside) . Curr Opin Lipidol . 2003;14(4):361–366
  39. Sun H , Unoki H , Wang X , et al.   Lipoprotein(a) enhances advanced atherosclerosis and vascular calcification in WHHL transgenic rabbits expressing human apolipoprotein(a) . J Biol Chem . 2002;277(49):47486–47492
  40. Fan J , Shimoyamada H , Sun H , et al.   Transgenic rabbits expressing human apolipoprotein(a) develop more extensive atherosclerotic lesions in response to a cholesterol-rich diet . Arterioscler Thromb Vasc Biol . 2001;21(1):88–94
  41. Williams JK , Bellinger DA , Nichols TC , et al.   Occlusive arterial thrombosis in cynomolgus monkeys with varying plasma concentrations of lipoprotein(a) . Arterioscler Thromb . 1993;13(4):548–554
  42. Beisiegel U , Niendorf A , Wolf K , et al.   Lipoprotein(a) in the arterial wall . Eur Heart J . 1990;11(suppl E):174–183
  43. Reblin T , Meyer N , Labeur C , et al.   Extraction of lipoprotein(a), apo B, and apo E from fresh human arterial wall and atherosclerotic plaques . Atherosclerosis . 1995;113(2):179–188
  44. Rodriguez CR , Seman LJ , Ordovas JM , et al.   Lipoprotein(a) and coronary heart disease . Chem Phys Lipids . 1994;67-68:389–398
  45. Schachinger V , Halle M , Minners J , et al.   Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation . J Am Coll Cardiol . 1997;30(4):927–934
  46. Wilmink HW , de Kleijn MJ , Bots ML , et al.   Lipoprotein(a) is associated with endothelial function in healthy postmenopausal women . Atherosclerosis . 2000;153(1):249–254
  47. Wu HD , Berglund L , Dimayuga C , et al.   High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort . J Am Coll Cardiol . 2004;43(10):1828–1833
  48. Schreiner PJ , Morrisett JD , Sharrett AR , et al.   Lipoprotein[a] as a risk factor for preclinical atherosclerosis . Arterioscler Thromb . 1993;13(6):826–833
  49. Velmurugan K , Deepa R , Ravikumar R , et al.   Relationship of lipoprotein(a) with intimal medial thickness of the carotid artery in Type 2 diabetic patients in south India . Diabet Med . 2003;20(6):455–461
  50. Schreiner PJ , Heiss G , Tyroler HA , et al.   Race and gender differences in the association of Lp(a) with carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study . Arterioscler Thromb Vasc Biol . 1996;16(3):471–478
  51. Ryu SK , Hong BK , Kwon HM , et al.   Age-related contribution of Lp(a) with coronary artery calcification in patients with acute coronary syndrome (a potential role of metabolic disorder in calcified plaque) . Yonsei Med J . 2003;44(3):445–453
  52. Superko HR , Hecht HS . Metabolic disorders contribute to subclinical coronary atherosclerosis in patients with coronary calcification . Am J Cardiol . 2001;88(3):260–264
  53. Peltier M , Iannetta Peltier MC , Sarano ME , et al.   Elevated serum lipoprotein(a) level is an independent marker of severity of thoracic aortic atherosclerosis . Chest . 2002;121(5):1589–1594
  54. Terres W , Tatsis E , Pfalzer B , et al.   Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a) . Circulation . 1995;91(4):948–950
  55. Dangas G , Ambrose JA , D’Agate DJ , et al.   Correlation of serum lipoprotein(a) with the angiographic and clinical presentation of coronary artery disease . Am J Cardiol . 1999;83(4):583–585 A7
  56. Matsumoto Y , Daida H , Watanabe Y , et al.   High level of lipoprotein(a) is a strong predictor for progression of coronary artery disease . J Atheroscler Thromb . 1998;5(2):47–53
  57. Tamura A , Watanabe T , Mikuriya Y , et al.   Serum lipoprotein(a) concentrations are related to coronary disease progression without new myocardial infarction . Br Heart J . 1995;74(4):365–369
  58. Zampoulakis JD , Kyriakousi AA , Poralis KA , et al.   Lipoprotein(a) is related to the extent of lesions in the coronary vasculature and to unstable coronary syndromes . Clin Cardiol . 2000;23(12):895–900
  59. Wang XL , Cranney G , Wilcken DE . Lp(a) and conventional risk profiles predict the severity of coronary stenosis in high-risk hospital-based patients . Aust NZ J Med . 2000;30(3):333–338
  60. Wang XL , Tam C , Mc Credie R , et al.   Determinants of severity of coronary artery disease in Australian men and women . Circulation . 1994;89:1974–1981
  61. Gazzaruso C , Geroldi D , Garzaniti A , et al.   Apolipoprotein(a) phenotypes as genetic markers of coronary atherosclerosis severity . Int J Cardiol . 1998;64(3):277–284
  62. Dangas G , Mehran R , Harpel PC , et al.   Lipoprotein(a) and inflammation in human coronary atheroma (association with the severity of clinical presentation) . J Am Coll Cardiol . 1998;32(7):2035–2042
  63. Katsouras CS , Karabina SA , Tambaki AP , et al.   Serum lipoprotein(a) concentrations and apolipoprotein(a) isoforms (association with the severity of clinical presentation in patients with coronary heart disease) . J Cardiovasc Risk . 2001;8(5):311–317
  64. Gazzaruso C , Garzaniti A , Buscaglia P , et al.   Lipoprotein(a) levels and apolipoprotein(a) polymorphism in type 1 diabetes mellitus (relationships to microvascular and neurological complications) . Acta Diabetol . 1998;35(1):13–18
  65. Kronenberg F , Kronenberg MF , Kiechl S , et al.   Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis (prospective results from the Bruneck study) . Circulation . 1999;100(11):1154–1160
  66. Gazzaruso C , Garzaniti A , Giordanetti S , et al.   Assessment of asymptomatic coronary artery disease in apparently uncomplicated type 2 diabetic patients (a role for lipoprotein(a) and apolipoprotein(a) polymorphism) . Diabetes Care . 2002;25(8):1418–1424
  67. Budde T , Fechtrup C , Bosenberg E , et al.   Plasma Lp(a) levels correlate with number, severity, and length–extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis . Arterioscler Thromb . 1994;14(11):1730–1736
  68. Miwa K , Nakagawa K , Yoshida N , et al.   Lipoprotein(a) is a risk factor for occurrence of acute myocardial infarction in patients with coronary vasospasm . J Am Coll Cardiol . 2000;35(5):1200–1205
  69. Stubbs P , Seed M , Lane D , et al.   Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes . Eur Heart J . 1998;19(9):1355–1364
  70. Lundstam U , Herlitz J , Karlsson T , et al.   Serum lipids, lipoprotein(a) level, and apolipoprotein(a) isoforms as prognostic markers in patients with coronary heart disease . J Intern Med . 2002;251(2):111–118
  71. Ohashi H , Oda H , Ohno M , et al.   Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients . Kidney Int Suppl . 1999;71:S242–S244
  72. Glader CA , Birgander LS , Stenlund H , et al.   Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden . J Intern Med . 2002;252(1):27–35
  73. Hoefler G , Harnoncourt F , Paschke E , et al.   Lipoprotein Lp(a). A risk factor for myocardial infarction . Arteriosclerosis . 1988;8(4):398–401
  74. Durrington PN , Ishola M , Hunt L , et al.   Apolipoproteins (a), AI, and B and parental history in men with early onset ischaemic heart disease . Lancet . 1988;1(8594):1070–1073
  75. Wilcken DE , Wang XL , Greenwood J , et al.   Lipoprotein(a) and apolipoproteins B and A-1 in children and coronary vascular events in their grandparents . J Pediatr . 1993;123(4):519–526
  76. Vella JC , Jover E . Relation of lipoprotein(a) in 11- to 19-year-old adolescents to parental cardiovascular heart disease . Clin Chem . 1993;39(3):477–480
  77. Hegele RA , Connelly P , Cullen-Dean G , et al.   Elevated plasma lipoprotein(a) associated with abnormal stress thallium scans in children with familial hypercholesterolemia . Am J Cardiol . 1993;72(5):402–406
  78. Peros E , Geroldi D , D’Angelo A , et al.   Apolipoprotein(a) phenotypes are reliable biomarkers for familial aggregation of coronary heart disease . Int J Mol Med . 2004;13(2):243–247
  79. Kostner GM , Czinner A , Pfeiffer KH , et al.   Lipoprotein(a) concentrations as risk indicators for atherosclerosis . Arch Dis Child . 1991;66(9):1054–1056
  80. Wilcken DE , Wang XL , Dudman NP . The relationship between infant and parent Lp(a) levels . Chem Phys Lipids . 1994;67-68:299–304
  81. Srinivasan SR , Dahlen GH , Jarpa RA , et al.   Racial (black-white) differences in serum lipoprotein(a) distribution and its relation to parental myocardial infarction in children. Bogalusa Heart Study . Circulation . 1991;84(1):160–167
  82. Pay S , Ozcan N , Tokgozoglu SL . Elevated Lp(a) is the most frequent familial lipoprotein disorder leading to premature myocardial infarction in a country with low cholesterol levels . Int J Cardiol . 1997;60(3):301–305
  83. Torbus-Lisiecka B , Bukowska H , Jastrzebska M , et al.   Lp(a), homocysteine and a family history of early ischemic cerebral stroke . Nutr Metab Cardiovasc Dis . 2001;11(suppl 5):52–59
  84. Orth-Gomer K , Mittleman MA , Schenck-Gustafsson K , et al.   Lipoprotein(a) as a determinant of coronary heart disease in young women . Circulation . 1997;95(2):329–334
  85. Austin MA , Sandholzer C , Selby JV , et al.   Lipoprotein(a) in women twins (heritability and relationship to apolipoprotein(a) phenotypes) . Am J Hum Genet . 1992;51(4):829–840
  86. Lindahl G , Gersdorf E , Menzel HJ , et al.   The gene for the Lp(a)-specific glycoprotein is closely linked to the gene for plasminogen on chromosome 6 . Hum Genet . 1989;81(2):149–152
  87. Rifai N , Heiss G , Doetsch K . Lipoprotein(a) at birth, in blacks and whites . Atherosclerosis . 1992;92(2-3):123–129
  88. Gazzaruso C , Garzaniti A , Buscaglia P , et al.   Association between apolipoprotein(a) phenotypes and coronary heart disease at a young age . J Am Coll Cardiol . 1999;33(1):157–163
  89. Kazumi T , Maeda T , Masuda T , et al.   Concurrent development of hemiplegia and angina pectoris in a 46-year-old man with familial hypercholesterolemia and elevated serum Lp(a) concentrations . J Atheroscler Thromb . 1994;1(2):129–131
  90. Isser HS , Puri VK , Narain VS , et al.   Lipoprotein(a) and lipid levels in young patients with myocardial infarction and their first-degree relatives . Indian Heart J . 2001;53(4):463–466
  91. Sandkamp M , Assman G . Lipoprotein(a) in PROCAM participants and young myocardial infarction survivors . In:  Scanu A editors. Lipoprotein(a) . San Diego, CA: Academic Press; 1990;p. 205–209
  92. Dahlen GH . Incidence of Lp(a) lipoproteins among populations . In:  Scanu AM editors. Lipoprotein(a) . San Diego, CA: Academic Press; 1990;p. 151–173
  93. Parlavecchia M , Pancaldi A , Taramelli R , et al.   Evidence that apolipoprotein(a) phenotype is a risk factor for coronary artery disease in men < 55 years of age . Am J Cardiol . 1994;74(4):346–351
  94. Dahlen GH , Berg K , Gillnas T , et al.   Lp(a) lipoprotein/pre-beta1-lipoprotein in Swedish middle-aged males and in patients with coronary heart disease . Clin Genet . 1975;7(4):334–341
  95. Danesh J , Collins R , Peto R . Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies . Circulation . 2000;102(10):1082–1085
  96. Pepin JM , O’Neil JA , Hoff HF . Quantification of apo[a] and apoB in human atherosclerotic lesions . J Lipid Res . 1991;32(2):317–327
  97. Kreuzer J , Lloyd MB , Bok D , et al.   Lipoprotein(a) displays increased accumulation compared with low-density lipoprotein in the murine arterial wall . Chem Phys Lipids . 1994;67-68:175–190
  98. Hearn JA , DeMaio SJ , Roubin GS , et al.   Predictive value of lipoprotein(a) and other serum lipoproteins in the angiographic diagnosis of coronary artery disease . Am J Cardiol . 1990;66(17):1176–1180
  99. Yamamoto H , Imazu M , Yamabe T , et al.   Risk factors for restenosis after percutaneous transluminal coronary angioplasty (role of lipoprotein(a)) . Am Heart J . 1995;130(6):1168–1173
  100. Miyata M , Biro S , Arima S , et al.   High serum concentration of lipoprotein(a) is a risk factor for restenosis after percutaneous transluminal coronary angioplasty in Japanese patients with single-vessel disease . Am Heart J . 1996;132(2 Pt. 1):269–273
  101. Desmarais RL , Sarembock IJ , Ayers CR , et al.   Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty . Circulation . 1995;91(5):1403–1409
  102. Chiarugi L , Prisco D , Antonucci E , et al.   Lipoprotein(a) and anticardiolipin antibodies are risk factors for clinically relevant restenosis after elective balloon percutaneous transluminal coronary angioplasty . Atherosclerosis . 2001;154(1):129–135
  103. Shah PK , Amin J . Low high density lipoprotein level is associated with increased restenosis rate after coronary angioplasty . Circulation . 1992;85(4):1279–1285
  104. Kim C , Gau GT , Allison TG . Relation of high lipoprotein(a) to other traditional atherosclerotic risk factors in patients with coronary heart disease . Am J Cardiol . 2003;91(11):1360–1363
  105. Igarashi Y , Aizawa Y , Satoh T , et al.   Predictors of adverse long-term outcome in acute myocardial infarction patients undergoing primary percutaneous transluminal coronary angioplasty (with special reference to the admission concentration of lipoprotein(a)) . Circ J . 2003;67(7):605–611
  106. Zairis MN , Ambrose JA , Manousakis SJ , et al.   The impact of plasma levels of C-reactive protein, lipoprotein(a) and homocysteine on the long-term prognosis after successful coronary stenting. The global evaluation of new events and restenosis after stent implantation study . J Am Coll Cardiol . 2002;40(8):1375
  107. Cushing GL , Gaubatz JW , Nava ML , et al.   Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation . Arteriosclerosis . 1989;9(5):593–603
  108. Rath M , Niendorf A , Reblin T , et al.   Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients . Arteriosclerosis . 1989;9(5):579–592
  109. Hoff HF , Beck G , Skibinski C , et al.   Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients . Circulation . 1988;77(6):1238–1244
  110. Daida GH , Lee YJ , Yokoi H , et al.  Low-Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group   Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein(a) levels with low-density lipoprotein apheresis . Am J Cardiol . 1994;73(15):1037–1040
  111. Yamaguchi H , Lee YJ , Daida H , et al.   Effectiveness of LDL-apheresis in preventing restenosis after percutaneous transluminal coronary angioplasty (PTCA) (LDL-apheresis angioplasty restenosis trial (L-ART)) . Chem Phys Lipids . 1994;67-68:399–403
  112. Adachi H , Niwa A , Shinoda T . Prevention of restenosis after coronary angioplasty with low-density lipoprotein apheresis . Artif Organs . 1995;19(12):1243–1247
  113. Christopher R , Kailasanatha KM , Nagaraja D , et al.   Case-control study of serum lipoprotein(a) and apolipoproteins A-I and B in stroke in the young . Acta Neurol Scand . 1996;94(2):127–130
  114. Nagayama M , Shinohara Y , Nagayama T . Lipoprotein(a) and ischemic cerebrovascular disease in young adults . Stroke . 1994;25(1):74–78
  115. Woo J , Lau E , Lam CW , et al.   Hypertension, lipoprotein(a), and apolipoprotein A-I as risk factors for stroke in the Chinese . Stroke . 1991;22(2):203–208
  116. Zenker G , Koltringer P , Bone G , et al.   Lipoprotein(a) as a strong indicator for cerebrovascular disease . Stroke . 1986;17(5):942–945
  117. Jurgens G , Koltringer P . Lipoprotein(a) in ischemic cerebrovascular disease (a new approach to the assessment of risk for stroke) . Neurology . 1987;37(3):513–515
  118. Schreiner PJ , Chambless LE , Brown SA , et al.   Lipoprotein(a) as a correlate of stroke and transient ischemic attack prevalence in a biracial cohort: the ARIC Study. Atherosclerosis Risk in Communities . Ann Epidemiol . 1994;4(5):351–359
  119. Murai A , Miyahara T , Fujimoto N , et al.   Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction . Atherosclerosis . 1986;59(2):199–204
  120. Shintani S , Kikuchi S , Hamaguchi H , et al.   High serum lipoprotein(a) levels are an independent risk factor for cerebral infarction . Stroke . 1993;24(7):965–969
  121. Sun L , Li Z , Zhang H , et al.   Pentanucleotide TTTTA repeat polymorphism of apolipoprotein(a) gene and plasma lipoprotein(a) are associated with ischemic and hemorrhagic stroke in Chinese (a multicenter case-control study in China) . Stroke . 2003;34(7):1617–1622
  122. Nowak-Gottl U , Strater R , Heinecke A , et al.   Lipoprotein(a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood . Blood . 1999;94(11):3678–3682
  123. Strater R , Becker S , von Eckardstein A , et al.   Prospective assessment of risk factors for recurrent stroke during childhood—a 5-year follow-up study . Lancet . 2002;360(9345):1540–1545
  124. Bostom AG , Gagnon DR , Cupples LA , et al.   A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women (The Framingham Heart Study) . Circulation . 1994;90(4):1688–1695
  125. Valentine RJ , Kaplan HS , Green R , et al.   Lipoprotein(a), homocysteine, and hypercoagulable states in young men with premature peripheral atherosclerosis (a prospective, controlled analysis) . J Vasc Surg . 1996;23(1):53–61 discussion 61-3
  126. Valentine RJ , Grayburn PA , Vega GL , et al.   Lp(a) lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white men . Arch Intern Med . 1994;154(7):801–806
  127. Lippi G , Veraldi GF , Dorucci V , et al.   Usefulness of lipids, lipoprotein(a) and fibrinogen measurements in identifying subjects at risk of occlusive complications following vascular and endovascular surgery . Scand J Clin Lab Invest . 1998;58(6):497–504
  128. Cantin B , Moorjani S , Dagenais GR , et al.   Lipoprotein(a) distribution in a French Canadian population and its relation to intermittent claudication (the Quebec Cardiovascular Study) . Am J Cardiol . 1995;75(17):1224–1228
  129. Tseng CH . Lipoprotein(a) is an independent risk factor for peripheral arterial disease in Chinese type 2 diabetic patients in Taiwan . Diabetes Care . 2004;27(2):517–521
  130. Widmann MD , Sumpio BE . Lipoprotein(a) (a risk factor for peripheral vascular disease) . Ann Vasc Surg . 1993;7(5):446–451
  131. Koschinsky ML , Marcovina SM . The relationship between lipoprotein(a) and the complications of diabetes mellitus . Acta Diabetol . 2003;40(2):65–76
  132. Mohan A , Srinivasan V , Deepa R , et al.   Lipoprotein(a) (role in diabetes and its vascular complications) . J Assoc Physicians India . 2001;49:1100–1105
  133. Igarashi Y , Yamaura M , Ito M , et al.   Elevated serum lipoprotein(a) is a risk factor for left atrial thrombus in patients with chronic atrial fibrillation (a transesophageal echocardiographic study) . Am Heart J . 1998;136(6):965–971
  134. Csaszar A , Karadi I , Juhasz E , et al.   High lipoprotein(a) levels with predominance of high molecular weight apo(a) isoforms in patients with pulmonary embolism . Eur J Clin Invest . 1995;25(5):368–370
  135. Marcucci R , Liotta AA , Cellai AP , et al.   Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism . Am J Med . 2003;115(8):601–605
  136. Levy PJ , Gonzalez F , Sheridan D , et al.   Diffuse arterial thrombosis in a young man with elevated lipoprotein(a) and minimal atherosclerosis . Cardiovasc Surg . 1995;3(1):56–59
  137. Papagrigorakis E , Iliopoulos D , Asimacopoulos PJ , et al.   Lipoprotein(a) in plasma, arterial wall, and thrombus from patients with aortic aneurysm . Clin Genet . 1997;52(5):262–271
  138. Stewart BF , Siscovick D , Lind BK , et al.   Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study . J Am Coll Cardiol . 1997;29(3):630–634
  139. Gotoh T , Kuroda T , Yamasawa M , et al.   Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study) . Am J Cardiol . 1995;76(12):928–932
  140. Kapelrud H , Bangstad HJ , Dahl-Jorgensen K , et al.   Serum Lp(a) lipoprotein concentrations in insulin dependent diabetic patients with microalbuminuria . BMJ . 1991;303(6804):675–678
  141. Kronenberg F , Lingenhel A , Lhotta K , et al.   The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome . Kidney Int . 2004;65(2):606–612
  142. Kronenberg F , Konig P , Neyer U , et al.   Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis . J Am Soc Nephrol . 1995;6(1):110–120
  143. Longenecker JC , Coresh J , Marcovina SM , et al.   Lipoprotein(a) and prevalent cardiovascular disease in a dialysis population (the choices for healthy outcomes in caring for ESRD (CHOICE) study) . Am J Kidney Dis . 2003;42(1):108–116
  144. Astor BC , Eustace JA , Klag MJ , et al.   Race-specific association of lipoprotein(a) with vascular access interventions in hemodialysis patients (the CHOICE Study) . Kidney Int . 2002;61(3):1115–1123
  145. Koch M , Kutkuhn B , Trenkwalder E , et al.   Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients . J Am Soc Nephrol . 1997;8(12):1889–1898
  146. Webb AT , Reaveley DA , O’Donnell M , et al.   Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy . Nephrol Dial Transplant . 1995;10(3):354–357
  147. Cressman MD , Abood D , O’Neil J , et al.   Lp(a) and premature mortality during chronic hemodialysis treatment . Chem Phys Lipids . 1994;67-68:419–427
  148. Seed M , Hoppichler F , Reaveley D , et al.   Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia . N Engl J Med . 1990;322(21):1494–1499
  149. Armstrong VW , Cremer P , Eberle E , et al.   The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels . Atherosclerosis . 1986;62(3):249–257
  150. Maher VMG , Brown BG , Marcovina SM , et al.   Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a) . JAMA . 1995;274(22):1771–1774
  151. Schaefer EJ , Lamon-Fava S , Jenner JL , et al.   Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial . JAMA . 1994;271(13):999–1003
  152. Cantin B , Gagnon F , Moorjani S , et al.   Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study . J Am Coll Cardiol . 1998;31(3):519–525
  153. Cobbaert C , Jukema JW , Zwinderman AH , et al.  Regression Growth Evaluation Statin Study (REGRESS) Study Group   Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol . J Am Coll Cardiol . 1997;30(6):1491–1499
  154. Grover SA , Coupal L , Hu XP . Identifying adults at increased risk of coronary disease . How well do the current cholesterol guidelines work? JAMA . 1995;274(10):801–806
  155. Stampfer MJ , Sacks FM , Salvini S , et al.   A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction . N Engl J Med . 1991;325(6):373–381
  156. Solymoss BC , Marcil M , Wesolowska E , et al.   Relation of coronary artery disease in women 60 years of age to the combined elevation of serum lipoprotein(a) and total cholesterol to high-density cholesterol ratio . Am J Cardiol . 1993;72(17):1215–1219
  157. Rainwater DL , Ludwig MJ , Haffner SM , et al.   Lipid and lipoprotein factors associated with variation in Lp(a) density . Arterioscler Thromb Vasc Biol . 1995;15(3):313–319
  158. Nago N , Kayaba K , Hiraoka J , et al.   Lipoprotein(a) levels in the Japanese population (influence of age and sex, and relation to atherosclerotic risk factors. The Jichi Medical School Cohort Study) . Am J Epidemiol . 1995;141(9):815–821
  159. Sechi LA , Kronenberg F , De Carli S , et al.   Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension . JAMA . 1997;277(21):1689–1695
  160. Gazzaruso C , Garzaniti A , Falcone C , et al.   Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary artery disease in Type 2 diabetic patients and in non-diabetic subjects . Diabet Med . 2001;18(7):589–594
  161. Ruiz J , Thillet J , Huby T , et al.   Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes . Diabetologia . 1994;37(6):585–591
  162. Agewall S , Fagerberg B . Lipoprotein(a) was an independent predictor for major coronary events in treated hypertensive men . Clin Cardiol . 2002;25(6):287–290
  163. Harpel PC , Zhang X , Borth W . Homocysteine and hemostasis (pathogenic mechanisms predisposing to thrombosis) . J Nutr . 1996;126(suppl 4):1285S–1289S
  164. Foody JM , Milberg JA , Robinson K , et al.   Homocysteine and lipoprotein(a) interact to increase CAD risk in young men and women . Arterioscler Thromb Vasc Biol . 2000;20(2):493–499
  165. Harpel PC , Chang VT , Borth W . Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin (a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism) . Proc Natl Acad Sci USA . 1992;89(21):10193–10197
  166. Cantin B , Despres JP , Lamarche B , et al.   Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study) . Am J Cardiol . 2002;89(6):662–666
  167. Gerdes LU , Gerdes C , Kervinen K , et al.   The apolipoprotein epsilon 4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction (a substudy of the Scandinavian simvastatin survival study) . Circulation . 2000;101(12):1366–1371
  168. Gazzaruso C , Buscaglia P , Garzaniti A , et al.   Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary heart disease in patients with essential hypertension . J Hypertens . 1997;15(3):227–235
  169. Hopkins PN , Hunt SC , Schreiner PJ , et al.   Lipoprotein(a) interactions with lipid and non-lipid risk factors in patients with early onset coronary artery disease (results from the NHLBI Family Heart Study) . Atherosclerosis . 1998;141(2):333–345
  170. Howard BV , Le NA , Belcher JD , et al.   Concentrations of Lp(a) in black and white young adults (relations to risk factors for cardiovascular disease) . Ann Epidemiol . 1994;4(5):341–350
  171. Wang W , Hu D , Lee ET , et al.   Lipoprotein(a) in American Indians is low and not independently associated with cardiovascular disease. The Strong Heart Study . Ann Epidemiol . 2002;12(2):107–114
  172. Enas EA , Senthilkumar A , Chacko V , Puthumana N . Dyslipidemia among Indo-Asians (strategies for identification and management) . Brit J Diabetes Vasc Dis . 2005;5:81–90
  173. Hughes K , Aw TC , Kuperan P , et al.   Central obesity, insulin resistance, syndrome X, lipoprotein(a), and cardiovascular risk in Indians, Malays, and Chinese in Singapore . J Epidemiol Community Health . 1997;51(4):394–399
  174. Low PS , Heng CK , Saha N , et al.   Racial variation of cord plasma lipoprotein(a) levels in relation to coronary risk level (a study in three ethnic groups in Singapore) . Pediatr Res . 1996;40(5):718–722
  175. Sandholzer C , Hallman DM , Saha N , et al.   Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups . Hum Genet . 1991;86(6):607–614
  176. Parra HJ , Arveiler D , Evans AE , et al.   A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study . Arterioscler Thromb . 1992;12(6):701–707
  177. Haffner SM , Gruber KK , Morales PA , et al.   Lipoprotein(a) concentrations in Mexican Americans and non-Hispanic whites (The San Antonio Heart Study) . Am J Epidemiol . 1992;136(9):1060–1068
  178. Bhatnagar D , Anand IS , Durrington PN , et al.   Coronary risk factors in people from the Indian subcontinent living in west London and their siblings in India . Lancet . 1995;345(8947):405–409
  179. Sakai Y , Tomobuchi Y , Toyoda Y , et al.   A premenopausal woman presenting with acute myocardial infarction of three different coronary vessels within 1 year (role of lipoprotein(a)) . Jpn Circ J . 1998;62(11):849–853
  180. Labeur C , De Bacquer D , De Backer G , et al.   Plasma lipoprotein(a) values and severity of coronary artery disease in a large population of patients undergoing coronary angiography . Clin Chem . 1992;38(11):2261–2266
  181. Sunayama S , Daida H , Mokuno H , et al.   Lack of increased coronary atherosclerotic risk due to elevated lipoprotein(a) in women > or = 55 years of age . Circulation . 1996;94(6):1263–1268
  182. Shlipak MG , Simon JA , Vittinghoff E , et al.   Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause . JAMA . 2000;283(14):1845–1852
  183. Jenner JL , Ordovas JM , Lamon-Fava S , et al.   Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study . Circulation . 1993;87(4):1135–1141
  184. Salobir B , Sabovic M , Peternel P , et al.   Fibrinolytic parameters and lipoprotein(a) in young women with myocardial infarction . Angiology . 2002;53(2):157–163
  185. Hahmann HW , Schatzer-Klotz D , Bunte T , et al.   The significance of high levels of lipoprotein(a) compared with established risk factors in premature coronary artery disease (differences between men and women) . Atherosclerosis . 1999;144(1):221–228
  186. Palaniappan L , Anthony MN , Mahesh C , et al.   Cardiovascular risk factors in ethnic minority women aged less-than-or-equal 30 years . Am J Cardiol . 2002;89(5):524–529
  187. Jha P , Enas E , Yusuf S . Coronary artery disease in Asian Indians (prevalence and risk factors) . Asian Am Pac Isl J Health . 1993;1(2):163–175
  188. Enas EA , Senthilkumar A , Juturu V , et al.   Coronary artery disease in women . Indian Heart J . 2001;53(3):282–292
  189. Ogunyemi D , Cuellar F , Ku W , et al.   Association between inherited thrombophilias, antiphospholipid antibodies, and lipoprotein A levels and venous thromboembolism in pregnancy . Am J Perinatol . 2003;20(1):17–24
  190. Berg K , Roald B , Sande H . High Lp(a) lipoprotein level in maternal serum may interfere with placental circulation and cause fetal growth retardation . Clin Genet . 1994;46:52–56 (1 Spec. No.)
  191. van Pampus MG , Koopman MM , Wolf H , et al.   Lipoprotein(a) concentrations in women with a history of severe preeclampsia—a case control study . Thromb Haemost . 1999;82(1):10–13
  192. Crook D , Howell R , Sidhu M , et al.   Elevated serum lipoprotein(a) levels in young women with endometriosis . Metabolism . 1997;46(7):735–739
  193. Atsumi T , Khamashta MA , Andujar C , et al.   Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome . J Rheumatol . 1998;25(1):69–73
  194. Yamazaki M , Asakura H , Jokaji H , et al.   Plasma levels of lipoprotein(a) are elevated in patients with the antiphospholipid antibody syndrome . Thromb Haemost . 1994;71(4):424–427
  195. Szczepanski M , Bauer A , Gardas A , et al.   Antiphospholipid antibodies and lipoprotein(a) in women with recurrent fetal loss . Int J Gynaecol Obstet . 1998;61(1):39–44
  196. Husby H , Roald B , Schjetlein R , et al.   High levels of Lp(a) lipoprotein in a family with cases of severe pre-eclampsia . Clin Genet . 1996;50(1):47–49
  197. Ariyo AA , Thach C , Tracy R . Lp(a) lipoprotein, vascular disease, and mortality in the elderly . N Engl J Med . 2003;349(22):2108–2115
  198. Rhoads GG , Dahlen G , Berg K , et al.   Lp(a) lipoprotein as a risk factor for myocardial infarction . JAMA . 1986;256(18):2540–2544
  199. Foody JM , Milberg JA , Pearce GL , et al.   Lipoprotein(a) associated with coronary artery disease in older women (age and gender analysis) . Atherosclerosis . 2000;153(2):445–451
  200. Berg K , Ro OC . Lp(a) lipoprotein level and longevity . Ann Genet . 1991;34(3-4):264–269
  201. Enas EA . Coronary artery disease epidemic in Indians (a cause for alarm and call for action) . J Indian Med Assoc . 2000;98(11):694–695 697-702
  202. Enas EA , Yusuf S , Mehta J . Prevalence of coronary artery disease in Asian Indians . Am J Cardiol . 1992;70:945–949
  203. Klatsky AL , Armstrong M . Cardiovascular risk factors among Asian Americans living in Northern California . Am J Public Health . 1991;81:1423–1428
  204. Hughes LO , Raval U , Raftery E . First myocardial infarctions in Asian and White men . BMJ . 1989;298:1345–1350
  205. Balarajan R . Ethnic differences in mortality from ischaemic heart disease and cerebrovascular disease in England and Wales . BMJ . 1991;302(6776):560–564
  206. Chuang CZ , Subramaniam PN , LeGardeur BY , et al.   Risk factors for coronary artery disease and levels of lipoprotein(a) and fat-soluble antioxidant vitamins in Asian Indians of USA . Indian Heart J . 1998;50(3):285–291
  207. Enas EA . Cardiovascular diseases in Asian Americans and Pacific Islanders . Asian Am Pac Islander J Health . 1996;4:119–120
  208. Enas EA , Garg A , Davidson MA , et al.   Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America . Indian Heart J . 1996;48(4):343–353
  209. Wild SH , Fortmann SP , Marcovina SM . A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants . Arterioscler Thromb Vasc Biol . 1997;17(2):239–245
  210. Grundy SM . Primary prevention of coronary heart disease (integrating risk assessment with intervention) . Circulation . 1999;100(9):988–998
  211. Forouhi N , McKeigue P . How far can risk factors account for excess coronary mortality in South Asians? . Can J Cardiol . 1997;13(suppl B):47B
  212. Miller GJ , Beckles GL , Maude GH , et al.   Ethnicity and other characteristics predictive of coronary heart disease in a developing community (principal results of the St James Survey, Trinidad) . Int J Epidemiol . 1989;18(4):808–817
  213. Kamath SK , Hussain EA , Amin D , et al.   Cardiovascular disease risk factors in 2 distinct ethnic groups (Indian and Pakistani compared with American premenopausal women) . Am J Clin Nutr . 1999;69(4):621–631
  214. Superko HR , Enas EA , Kotha P , et al.   Impaired cholesterol transport in Asian Indians . J Am Coll Cardiol . 2001;37:300A
  215. Cobbaert C , Kesteloot H . Serum lipoprotein(a) levels in racially different populations . Am J Epidemiol . 1992;136(4):441–449
  216. Refsum H , Yajnik CS , Gadkari M , et al.   Hyperhomocysteinemia and elevated methylmalonic acid indicate a high prevalence of cobalamin deficiency in Asian Indians . Am J Clin Nutr . 2001;74(2):233–241
  217. Anand S , Yusuf S , Vuksan V , et al.   Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada (the Study of Health Assessment and Risk in Ethnic groups (SHARE)) . Lancet . 2000;356(9226):279–284
  218. Proudler AJ , Godsland IF , Bruce R , et al.   Lipid and carbohydrate metabolic risk markers for coronary heart disease and blood pressure in healthy non-obese premenopausal women of different racial origins in the United Kingdom . Metabolism . 1996;45(3):328–333
  219. Chopra V , Vasisht S , Gulati S , et al.   Serum levels of lipoprotein(a) and other lipids in angiographically defined coronary artery disease patients and healthy blood bank donors . Indian J Med Sci . 2000;54(7):284–289
  220. Gupta R , Kastia S , Rastogi S , et al.   Lipoprotein(a) in coronary heart disease (a case-control study) . Indian Heart J . 2000;52(4):407–410
  221. Gupta R , Vasisht S , Bahl VK , et al.   Correlation of lipoprotein(a) to angiographically defined coronary artery disease in Indians . Int J Cardiol . 1996;57(3):265–270
  222. Mammi MV , Pavithran K , Abdu Rahiman P , et al.   Acute myocardial infarction in north Kerala—a 20 year hospital based study . Indian Heart J . 1991;43(2):93–96
  223. Bahuleyan CG . Hospital data on coronary heart disease from North Kerala . In:  Vijayaraghavan G editors. Cardiovascular Disease Prevention . Trivandrum, India: Trivandrum Medical College; 1996;p. 54–59
  224. Enas EA . Why is there an epidemic of malignant CAD in young Indians? . Asian J Clin Cardiol . 1998;1:43–59
  225. Muthusamy V , Amuthan V , Kumaravel V . Lipoprotein(a) and premature coronary artery disease . Indian Heart J . 2000;52:765
  226. Deepa R , Mohan A , Rema M , et al.   Lipoprotein(a) in South Indian type 2 diabetic subjects in relation to diabetic vascular complications . J Assoc Physicians India . 2002;50(5):657–661
  227. Enas EA . Lipoprotein(a) is an important genetic risk factor for coronary artery disease in Asian Indians . Am J Cardiol . 2001;88:201–202
  228. Enas EA , Jacob ST . Emerging noninvasive biochemical measures (potential explanation for ethnic differences in cardiovascular risk) . Arch Intern Med . 1999;159:1812–1813
  229. Misra A . Atherosclerosis in Indians and lipoprotein(a) . J Assoc Physicians India . 1999;47(3):313–317
  230. Enas EA , Senthilkumar A , Chennikkara H , et al.   Prudent diet and preventive nutrition from pediatrics to geriatrics (current knowledge and practical recommendations) . Indian Heart J . 2003;55(4):310–338
  231. Xiong ZW , Wahlqvist ML , Ibiebele TI , et al.   Relationship between plasma lipoprotein(a), apolipoprotein(a) phenotypes, and other coronary heart disease risk factors in a Melbourne South Asian population . Clin Biochem . 2004;37(4):305–311
  232. Sundram K , Ismail A , Hayes KC , et al.   Trans (elaidic) fatty acids adversely affect the lipoprotein profile relative to specific saturated fatty acids in humans . J Nutr . 1997;127(3):514S–520S
  233. Guyton JR , Dahlen GH , Patsch W , et al.   Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B . Arteriosclerosis . 1985;5(3):265–272
  234. Heyden S , Von Eckardstein A , Schulte H , et al.   Raised lipoprotein(a) in hypercholesterolaemic black students compared to age-matched whites in North and South Carolina . Int J Epidemiol . 1994;23(2):301–306
  235. Marcovina SM , Albers JJ , Jacobs DR , et al.   Lipoprotein[a] concentrations and apolipoprotein[a] phenotypes in Caucasians and African Americans. The CARDIA study . Arterioscler Thromb . 1993;13(7):1037–1045
  236. Schreiner PJ . Lipoprotein(a) as a risk factor for preclinical atherosclerotic disease in a biracial cohort (the Atherosclerosis Risk in Communities (ARIC) Study) . Chem Phys Lipids . 1994;67-68:405–410
  237. Sharrett AR , Ballantyne CM , Coady SA , et al.   Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions (The Atherosclerosis Risk in Communities (ARIC) Study) . Circulation . 2001;104(10):1108–1113
  238. Moliterno DJ , Jokinen EV , Miserez AR , et al.   No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans . Arterioscler Thromb Vasc Biol . 1995;15(7):850–855
  239. NCEP III . Third Report of the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (National Institute of Health) . 2002; September2002. Report No. 02-5215.
  240. Brown SA , Hutchinson R , Morrisett J , et al.   Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis Risk in Communities (ARIC) Study . Arterioscler Thromb . 1993;13(8):1139–1158
  241. Wilcosky TC , Kwiterovich PO , Glueck CJ , et al.   Dyslipoproteinemia in black participants. The Lipid Research Clinics Program Prevalence Study . Circulation . 1986;73(1 Pt. 2):I119–I125
  242. Paultre F , Pearson TA , Weil HF , et al.   High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men . Arterioscler Thromb Vasc Biol . 2000;20(12):2619–2624
  243. Marcovina SM , Albers JJ , Wijsman E , et al.   Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans . J Lipid Res . 1996;37(12):2569–2585
  244. Paultre F , Tuck CH , Boden-Albala B , et al.   Relation of Apo(a) size to carotid atherosclerosis in an elderly multiethnic population . Arterioscler Thromb Vasc Biol . 2002;22(1):141–146
  245. Ridker PM , Hennekens CH , Stampfer MJ . A prospective study of lipoprotein(a) and the risk of myocardial infarction . JAMA . 1993;270(18):2195–2199
  246. Jauhiainen M , Koskinen P , Ehnholm C , et al.   Lipoprotein(a) and coronary heart disease risk (a nested case-control study of the Helsinki Heart Study participants) . Atherosclerosis . 1991;89(1):59–67
  247. Ridker PM , Stampfer MJ , Hennekens CH . Plasma concentration of lipoprotein(a) and the risk of future stroke . JAMA . 1995;273(16):1269–1273
  248. Klausen IC , Sjol A , Hansen PS , et al.   Apolipoprotein(a) isoforms and coronary heart disease in men (a nested case-control study) . Atherosclerosis . 1997;132(1):77–84
  249. Holmer SR , Hengstenberg C , Kraft HG , et al.   Association of polymorphisms of the apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction . Circulation . 2003;107(5):696–701
  250. Cremer P , Nagel D , Labrot B , et al.   Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors (results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS)) . Eur J Clin Invest . 1994;24(7):444–453
  251. Coleman MP , Key TJ , Wang DY , et al.   A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women . Atherosclerosis . 1992;92(2-3):177–185
  252. Sigurdsson G , Baldursdottir A , Sigvaldason H , et al.   Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men . Am J Cardiol . 1992;69(16):1251–1254
  253. Wald NJ , Law M , Watt HC , et al.   Apolipoproteins and ischaemic heart disease (implications for screening) . Lancet . 1994;343(8889):75–79
  254. Seed M , Ayres KL , Humphries SE , et al.   Lipoprotein(a) as a predictor of myocardial infarction in middle-aged men . Am J Med . 2001;110(1):22–27
  255. Rosengren A , Wilhelmsen L , Eriksson E , et al.   Lipoprotein(a) and coronary heart disease (a prospective case-control study in a general population sample of middle aged men) . BMJ . 1990;301(6763):1248–1251
  256. Simons L , Friedlander Y , Simons J , et al.   Lipoprotein(a) is not associated with coronary heart disease in the elderly (cross-sectional data from the Dubbo study) . Atherosclerosis . 1993;99(1):87–95
  257. Evans RW , Shpilberg O , Shaten BJ , et al.   Prospective association of lipoprotein(a) concentrations and apo(a) size with coronary heart disease among men in the Multiple Risk Factor Intervention Trial . J Clin Epidemiol . 2001;54(1):51–57
  258. Klausen IC , Beisiegel U , Menzel HJ , et al.   Apo(a) phenotypes and Lp(a) concentrations in offspring of men with and without myocardial infarction. The EARS Study. European Atherosclerosis Research Study . Arterioscler Thromb Vasc Biol . 1995;15(8):1001–1008
  259. Scanu AM . Lipoprotein(a) and the atherothrombotic process (mechanistic insights and clinical implications) . Curr Atheroscler Rep . 2003;5(2):106–113
  260. Marcovina SM , Zhang ZH , Gaur VP , et al.   Identification of 34 apolipoprotein(a) isoforms (differential expression of apolipoprotein(a) alleles between American blacks and whites) . Biochem Biophys Res Commun . 1993;191(3):1192–1196
  261. Brown SA , Morrisett JD , Boerwinkle E , et al.   The relation of lipoprotein[a] concentrations and apolipoprotein[a] phenotypes with asymptomatic atherosclerosis in subjects of the Atherosclerosis Risk in Communities (ARIC) Study . Arterioscler Thromb . 1993;13(11):1558–1566
  262. Kraft HG , Lingenhel A , Kochl S , et al.   Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease . Arterioscler Thromb Vasc Biol . 1996;16(6):713–719
  263. Farrer M , Game FL , Albers CJ , et al.   Coronary artery disease is associated with increased lipoprotein(a) concentrations independent of the size of circulating apolipoprotein(a) isoforms . Arterioscler Thromb . 1994;14(8):1272–1283
  264. Brazier L , Tiret L , Luc G , et al.   Sequence polymorphisms in the apolipoprotein(a) gene and their association with lipoprotein(a) levels and myocardial infarction. The ECTIM Study . Atherosclerosis . 1999;144(2):323–333
  265. Geethanjali FS , Jose VJ , Kanagasabapathy AS . Lipoprotein(a) phenotypes in south Indian patients with coronary artery disease . Indian Heart J . 2002;54(1):50–53
  266. Geethanjali FS , Luthra K , Lingenhel A , et al.   Analysis of the apo(a) size polymorphism in Asian Indian populations (association with Lp(a) concentration and coronary heart disease) . Atherosclerosis . 2003;169(1):121–130
  267. Gambhir JK , Gambhir D , Morreset J . Lipoprotein(a) in normal Indian subjects and and patients with coronary artery disease . Indian Heart J . 1998;50:563
  268. Kraft HG , Lingenhel A , Pang RW , et al.   Frequency distributions of apolipoprotein(a) kringle IV repeat alleles and their effects on lipoprotein(a) levels in Caucasian, Asian, and African populations (the distribution of null alleles is non-random) . Eur J Hum Genet . 1996;4(2):74–87
  269. Alfthan G , Pekkanen J , Jauhiainen M , et al.   Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study . Atherosclerosis . 1994;106(1):9–19
  270. Craig WY , Poulin SE , Forster NR , et al.   Effect of sample storage on the assay of lipoprotein(a) by commercially available radial immunodiffusion and enzyme-linked immunosorbent assay kits . Clin Chem . 1992;38(4):550–553
  271. Devanapalli B , Lee S , Mahajan D , et al.   Lipoprotein(a) in an immigrant Indian population sample in Australia . Br J Biomed Sci . 2002;59(2):119–122
  272. Kronenberg F , Trenkwalder E , Dieplinger H , et al.   Lipoprotein(a) in stored plasma samples and the ravages of time. Why epidemiological studies might fail . Arterioscler Thromb Vasc Biol . 1996;16(12):1568–1572
  273. Matsubara M , Akita H , Shibuya H , et al.   Decreased longevity in Japanese men, associated with low-molecular-weight apolipoprotein(a) phenotypes . Ann Clin Biochem . 2001;38(Pt. 2):120–123
  274. Serdar A , Yesilbursa D , Serdar Z . [Lipoprotein(a) as a risk factor for coronary artery disease in women and elderly patients] . Anadolu Kardiyol Derg . 2001;1(4):259–263 AXV-XVI
  275. Kulkarni KR , Garber DW , Jones MK , et al.   Identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodology . J Lipid Res . 1995;36(11):2291–2302
  276. Marcovina SM , Koschinsky ML , Albers JJ , et al.   Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease (recent advances and future directions) . Clin Chem . 2003;49(11):1785–1796
  277. Marcovina SM , Albers JJ , Gabel B , et al.   Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a) . Clin Chem . 1995;41(2):246–255
  278. Ridker PM , Stampfer MJ , Rifai N . Novel risk factors for systemic atherosclerosis (a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease) . JAMA . 2001;285(19):2481–2485
  279. Dati F , Tate JR , Marcovina SM , et al.   First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay—Lp(a) SRM 2B . Clin Chem Lab Med . 2004;42(6):670–676
  280. Marcovina SM , Albers JJ , Scanu AM , et al.   Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a) . Clin Chem . 2000;46(12):1956–1967
  281. Boerwinkle E , Leffert CC , Lin J , et al.   Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations . J Clin Invest . 1992;90(1):52–60
  282. Mooser V , Scheer D , Marcovina SM , et al.   The Apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African Americans . Am J Hum Genet . 1997;61(2):402–417
  283. Hubinger L , Mackinnon LT . The effect of endurance training on lipoprotein(a) [Lp(a)] levels in middle-aged males . Med Sci Sports Exerc . 1996;28(6):757–764
  284. Hubinger L , Mackinnon LT , Lepre F . Lipoprotein(a) [Lp(a)] levels in middle-aged male runners and sedentary controls . Med Sci Sports Exerc . 1995;27(4):490–496
  285. Fontana P , Mooser V , Bovet P , et al.   Dose-dependent inverse relationship between alcohol consumption and serum Lp(a) levels in black African males . Arterioscler Thromb Vasc Biol . 1999;19(4):1075–1082
  286. Marth E , Cazzolato G , Bittolo Bon G , et al.   Serum concentrations of Lipoprotein(a) and other lipoprotein parameters in heavy alcohol consumers . Ann Nutr Metab . 1982;26(1):56–62
  287. Jenkins DJ , Kendall CW , Marchie A , et al.   Dose response of almonds on coronary heart disease risk factors: blood lipids, oxidized low-density lipoproteins, lipoprotein(a), homocysteine, and pulmonary nitric oxide: a randomized, controlled, crossover trial . Circulation . 2002;106(11):1327–1332
  288. Clevidence BA , Judd JT , Schaefer EJ , et al.   Plasma lipoprotein(a) levels in men and women consuming diets enriched in saturated, cis-, or trans-monounsaturated fatty acids . Arterioscler Thromb Vasc Biol . 1997;17(9):1657–1661
  289. Mensink RP , Zock PL , Katan MB , et al.   Effect of dietary cis and trans fatty acids on serum lipoprotein[a] levels in humans . J Lipid Res . 1992;33(10):1493–1501
  290. Nestel PJ , Noakes M , Belling B , et al.   Plasma lipoprotein lipid and Lp[a] changes with substitution of elaidic acid for oleic acid in the diet . J Lipid Res . 1992;33(7):1029–1036
  291. Marcovina SM , Kennedy H , Bittolo Bon G , et al.   Fish intake, independent of apo(a) size, accounts for lower plasma lipoprotein(a) levels in Bantu fishermen of Tanzania (The Lugalawa Study) . Arterioscler Thromb Vasc Biol . 1999;19(5):1250–1256
  292. Eritsland J , Arnesen H , Berg K , et al.   Serum Lp(a) lipoprotein levels in patients with coronary artery disease and the influence of long-term n-3 fatty acid supplementation . Scand J Clin Lab Invest . 1995;55(4):295–300
  293. Milionis HJ , Efstathiadou Z , Tselepis AD , et al.   Lipoprotein(a) levels and apolipoprotein(a) isoform size in patients with subclinical hypothyroidism (effect of treatment with levothyroxine) . Thyroid . 2003;13(4):365–369
  294. Min WK , Lee J , Huh J . Relation between lipoprotein(a) concentrations in patients with acute-phase response and risk analysis for coronary heart disease . Clin Chem . 1997;43(10):1891–1895
  295. Maeda S , Abe A , Seishima M , et al.   Transient changes of serum lipoprotein(a) as an acute phase protein . Atherosclerosis . 1989;78(2-3):145–150
  296. Sweetnam PM , Bolton CH , Downs LG , et al.   Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease (the Caerphilly study) . Eur J Clin Invest . 2000;30(11):947–956
  297. Baldassarre D , Tremoli E , Franceschini G , et al.   Plasma lipoprotein(a) is an independent factor associated with carotid wall thickening in severely but not moderately hypercholesterolemic patients . Stroke . 1996;27(6):1044–1049
  298. Mishra TK , Routray S , Patnaik U , et al.   Lipoprotein(a) and lipid profile in young patients with angiographically proven coronary artery disease . Indian Heart J . 2001;53:585
  299. Dahlen GH , Stenlund H . Lp(a) lipoprotein is a major risk factor for cardiovascular disease (pathogenic mechanisms and clinical significance) . Clin Genet . 1997;52(5):272–280
  300. Hearn JA , Donohue B , Ba’albaki H , et al.   Usefulness of serum lipoprotein(a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty . Am J Cardiol . 1992;69(8):736–739
  301. Kulkarni KR , Garber DW , Marcovina SM , et al.   Quantification of cholesterol in all lipoprotein classes by the VAP-II method . J Lipid Res . 1994;35(1):159–168
  302. Scanu AM , Hinman J . Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels . Lipids . 2002;37(5):439–444
  303. Seman J , DeLuca C , Jenner JL , et al.   Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study . Clin Chem . 1999;45(7):1039–1046
  304. Thompson GR , Maher VM , Matthews S , et al.   Familial Hypercholesterolaemia Regression Study (a randomised trial of low-density-lipoprotein apheresis) . Lancet . 1995;345(8953):811–816
  305. Klausen IC , Gerdes LU , Meinertz H , et al.   Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration . Eur J Clin Invest . 1993;23(4):240–245
  306. van Wissen S , Smilde TJ , Trip MD , et al.   Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia . Heart . 2003;89(8):893–896
  307. Schaefer EJ , McNamara JR , Tayler T , et al.   Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects . Am J Cardiol . 2004;93(1):31–39
  308. Berg K , Dahlen G , Christophersen B , et al.   Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study . Clin Genet . 1997;52(5):254–261
  309. LaRosa JC , He J , Vupputuri S . Effect of statins on risk of coronary disease (a meta-analysis of randomized controlled trials) . JAMA . 1999;282(24):2340–2346
  310. Pitt B , Waters D , Brown WV , et al.  Atorvastatin versus Revascularization Treatment Investigators   Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease . N Engl J Med . 1999;341(2):70–76
  311. Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals (a randomised placebo-controlled trial) . Lancet . 2002;360(9326):7–22
  312. Cannon CP , Braunwald E , McCabe CH , et al.   Intensive versus moderate lipid lowering with statins after acute coronary syndromes . N Engl J Med . 2004;350(15):1495–1504
  313. Schwartz GG , Olsson AG , Ezekowitz MD , et al.   Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial . JAMA . 2001;285(13):1711–1718
  314. Shewmon DA , Stock JL , Rosen CJ , et al.   Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women . Arterioscler Thromb . 1994;14(10):1586–1593
  315. Carlson LA , Hamsten A , Asplund A . Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid . J Intern Med . 1989;226(4):271–276
  316. Davidson MH . Niacin (a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events) . Curr Atheroscler Rep . 2003;5(5):418–422
  317. Canner PL , Berge KG , Wenger NK , et al.   Fifteen year mortality in Coronary Drug Project patients (long-term benefit with niacin) . J Am Coll Cardiol . 1986;8(6):1245–1255
  318. Coronary Drug Project Research Group . Clofibrate and niacin in coronary heart disease . JAMA . 1975;231(4):360–381
  319. Morgan JM , Capuzzi DM , Guyton JR , et al.   Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia (a placebo-controlled trial) . J Cardiovasc Pharmacol Ther . 1996;1(3):195–202
  320. McKenney J . New perspectives on the use of niacin in the treatment of lipid disorders . Arch Intern Med . 2004;164(7):697–705
  321. Knopp RH , Alagona P , Davidson M , et al.   Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia . Metabolism . 1998;47(9):1097–1104
  322. Meyers CD , Carr MC , Park S , et al.   Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia . Ann Intern Med . 2003;139(12):996–1002
  323. Kashyap ML , McGovern ME , Berra K , et al.   Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia . Am J Cardiol . 2002;89(6):672–678
  324. Elam MB , Hunninghake DB , Davis KB , et al.   Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial . JAMA . 2000;284(10):1263–1270
  325. Grundy SM , Vega GL , McGovern ME , et al.   Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes (results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial) . Arch Intern Med . 2002;162(14):1568–1576
  326. Pan J , Van JT , Chan E , et al.   Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes . Metabolism . 2002;51(9):1120–1127
  327. Wolfe ML , Vartanian SF , Ross JL , et al.   Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia . Am J Cardiol . 2001;87(4):476–479
  328. Brown BG , Albers JJ , Fisher LD , et al.   Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B . N Engl J Med . 1990;323(19):1289–1298
  329. Brown BG , Zhao XQ , Chait A , et al.   Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease . N Engl J Med . 2001;345(22):1583–1592
  330. Bays HE , Dujovne CA , McGovern ME , et al.   Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]) . Am J Cardiol . 2003;91(6):667–672
  331. Akaike M , Azuma H , Kagawa A , et al.   Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases . Clin Chem . 2002;48(9):1454–1459
  332. Straube R , Kingreen H . Lipoprotein(a) immunapheresis in the treatment of familial lipoprotein(a) hyperlipoproteinemia in a patient with coronary heart disease . Ther Apher . 1998;2(3):243–245
  333. Armstrong VW , Schuff-Werner P , Eisenhauer T , et al.   Heparin extracorporeal LDL precipitation (HELP) (an effective apheresis procedure for lowering Lp(a) levels) . Chem Phys Lipids . 1994;67-68:315–321
  334. Kroon AA , Aengevaeren WR , van der Werf T , et al.   LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis . Circulation . 1996;93(10):1826–1835
  335. Harjai KJ . Potential new cardiovascular risk factors (left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen) . Ann Intern Med . 1999;131(5):376–386
  336. Hackam DG , Anand SS . Emerging risk factors for atherosclerotic vascular disease (a critical review of the evidence) . JAMA . 2003;290(7):932–940

 No financial information to disclose.

PII: S0011-5029(06)00013-7

doi: 10.1016/j.disamonth.2006.01.002

Disease-A-Month
Volume 52, Issue 1 , Pages 5-50 , January 2006

Article Tools

* Image Usage & Resolution